Replication of HIV within the CNS continues to be a hot topic, because it represents a viral reservoir that can complicate treatment, as well as control and prevention efforts.
“Super-spreaders” continue to play a major role in various epidemics, including tuberculosis and HIV infection.
Preliminary study results confirm that patient education and targeting those in higher-risk populations or who engage in high-risk behaviors continue to be important in preventing HIV transmission. Four specific recommendations here.
It is quite likely that we have entered a new era of treatment for individuals either mono-infected with HCV or co-infected with HCV/HIV. Details here.
The START trial is likely to provide a definitive answer to one of the most important clinical questions in HIV management: when is the optimal time to start antiretroviral therapy.
Better understanding of this complex condition can lead to better patient care and prevention. This week’s photo quiz offers several presentations to test your knowledge.
Stark defunding for AIDS research may lead to increased pharmaceutical influence, less population diversity in research, and dwindling new HIV-specific advances.
Hepatocellular Carcinoma Develops in HIV/HCV Coinfected Patients—Even After Sustained Viral Response
Hepatocellular carcinoma can develop in HIV/HCV-coinfected patients with a previous sustained virological response with interferon-based therapy. Continued surveillance for HCC with ultrasound examinations in patients with cirrhosis who respond to anti-HCV therapy is recommended.
Incomplete adherence with anti-retroviral therapy can be associated with higher levels of residual HIV-1 viremia, according to a new study. Details here.
People with HIV infection are at high risk for invasive meningococcal disease. Current guidelines do not recommend vaccination against meningococcal disease for patients with HIV infection, but these patients can choose to be vaccinated.